Moomoo AI 已提取核心信息
Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed a Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister all unsold shares of its common stock previously registered under a Registration Statement on Form S-3. This action follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law and seek stockholder approval for the dissolution. The board determined that the dissolution is in the best interests of the company and its stakeholders. The filing of the Post-Effective Amendment is a formal step to terminate the effectiveness of the Registration Statements and remove from registration any unsold securities, effectively ending the offerings of securities under these statements.
Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed a Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister all unsold shares of its common stock previously registered under a Registration Statement on Form S-3. This action follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law and seek stockholder approval for the dissolution. The board determined that the dissolution is in the best interests of the company and its stakeholders. The filing of the Post-Effective Amendment is a formal step to terminate the effectiveness of the Registration Statements and remove from registration any unsold securities, effectively ending the offerings of securities under these statements.
总部位于特拉华州的生物技术公司Evelo Biosciences, Inc. 已于2024年1月26日向美国证券交易委员会（SEC）提交了生效后第1号修正案，要求注销先前根据S-3表格注册声明注册的所有未售出普通股。该行动是在公司董事会于2023年11月21日决定根据《特拉华州通用公司法》解散公司并寻求股东批准解散之后采取的。董事会认为解散符合公司及其利益相关者的最大利益。提交生效后修正案是终止注册声明的有效性并从注册中删除任何未售出证券的正式步骤，实际上终止了根据这些声明发行的证券。
总部位于特拉华州的生物技术公司Evelo Biosciences, Inc. 已于2024年1月26日向美国证券交易委员会（SEC）提交了生效后第1号修正案，要求注销先前根据S-3表格注册声明注册的所有未售出普通股。该行动是在公司董事会于2023年11月21日决定根据《特拉华州通用公司法》解散公司并寻求股东批准解散之后采取的。董事会认为解散符合公司及其利益相关者的最大利益。提交生效后修正案是终止注册声明的有效性并从注册中删除任何未售出证券的正式步骤，实际上终止了根据这些声明发行的证券。
有用
没用
该公告为独立文件：